The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
ONLY
ARTICLE
Med Lett Drugs Ther. 2025 May 26;67(1729):e1-15 doi:10.58347/tml.2025.1729b
Disclosures
Principal Faculty- Mark Abramowicz, M.D., President has disclosed no relevant financial relationships.
- Jean-Marie Pflomm, Pharm.D., Editor in Chief has disclosed no relevant financial relationships.
- Michael Viscusi, Pharm.D., Associate Editor has disclosed no relevant financial relationships.
Objective(s)
Upon completion of this activity, the participant will be able to:
- Explain the current approach to the management of chronic heart failure.
- Discuss the pharmacologic options available for treatment of chronic heart failure and compare them based on their mechanism of action, efficacy, and potential adverse effects.
- Determine the most appropriate pharmacologic treatment for chronic heart failure with reduced ejection fraction for an individual patient.
© The Medical Letter, Inc. All Rights Reserved.
The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and
complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any
damage resulting from any error, inaccuracy, or omission.